Applied DNA Sciences (APDN) Stock Price, News & Analysis

Company Overview

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Key Stats

• Today's Range: $4.77 to $4.98
• 50-Day Range: $4.51 to $8.70
• 52-Week Range: $4.37 to $2,655.00
• Volume: 31,241 shs
• Average Volume: 95,245 shs
• Market Capitalization: $2.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Applied DNA Sciences Stock Analysis - MarketRank™

Applied DNA Sciences scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Applied DNA Sciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Applied DNA Sciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Applied DNA Sciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Applied DNA Sciences has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.19% of the float of Applied DNA Sciences has been sold short.

Short Interest Ratio / Days to Cover

Applied DNA Sciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Applied DNA Sciences has recently decreased by 69.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Applied DNA Sciences does not currently pay a dividend.

Dividend Growth

Applied DNA Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.19% of the float of Applied DNA Sciences has been sold short.

Short Interest Ratio / Days to Cover

Applied DNA Sciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Applied DNA Sciences has recently decreased by 69.51%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Applied DNA Sciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Industrials companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Applied DNA Sciences this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for APDN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

4 people have added Applied DNA Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Applied DNA Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.17% of the stock of Applied DNA Sciences is held by insiders.

Percentage Held by Institutions

Only 22.22% of the stock of Applied DNA Sciences is held by institutions.

APDN Stock Analysis - Frequently Asked Questions

How have APDN shares performed this year?

Applied DNA Sciences' stock was trading at $153.00 at the beginning of the year. Since then, APDN shares have decreased by 96.8% and is now trading at $4.82.

How were Applied DNA Sciences' earnings last quarter?

Applied DNA Sciences Inc (NASDAQ:APDN) released its quarterly earnings data on Thursday, May, 15th. The technology company reported ($230.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($45.00) by $185.25. The technology company had revenue of $0.98 million for the quarter, compared to analysts' expectations of $1.19 million. Applied DNA Sciences had a negative trailing twelve-month return on equity of 66.95% and a negative net margin of 194.14%.

When did Applied DNA Sciences' stock split?

Shares of Applied DNA Sciences reverse split on Sunday, June 1st 2025.The 1-15 reverse split was announced on Sunday, June 1st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Applied DNA Sciences?

Shares of APDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Applied DNA Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied DNA Sciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), Virgin Galactic (SPCE), AST SpaceMobile (ASTS) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/30/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Industrials
• Industry: PROTECTION - SFTY
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:APDN
• CIK: 744452
• Web: www.adnas.com
• Phone: (631) 240-8800
• Fax: 631-240-8900
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($537.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.99 million
• Net Margins: -194.14%
• Pretax Margin: -197.02%
• Return on Equity: -66.95%
• Return on Assets: -50.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.45
• Quick Ratio: 4.27

Sales & Book Value

• Annual Sales: $3.43 million
• Price / Sales: 0.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $215.25 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 440,000
• Free Float: 434,000
• Market Cap: $2.15 million
• Optionable: Optionable
• Beta: 0.07